Factors Associated with Significant Platelet Count Improvement in Thrombocytopenic Chronic Hepatitis C Patients Receiving Direct-Acting Antivirals
Authors:
- Yen-Chun ChenYCYen-Chun Chen
- Te-Sheng ChangTCTe-Sheng Chang
- Chien-Hung ChenCCChien-Hung Chen
- Pin-Nan ChengPCPin-Nan Cheng
- Ching-Chu LoCLChing-Chu Lo
- Lein-Ray MoLMLein-Ray Mo
- Chun-Ting ChenCCChun-Ting Chen
- Chung-Feng HuangCHChung-Feng Huang
- Hsing-Tao KuoHKHsing-Tao Kuo
- Yi-Hsiang HuangYHYi-Hsiang Huang
- Chi-Ming TaiCTChi-Ming Tai
- Cheng-Yuan PengCPCheng-Yuan Peng
Open Access
Abstract
To clarify the predictive factors of significant platelet count improvement in thrombocytopenic chronic hepatitis C (CHC) patients. CHC patients with baseline platelet counts of 3/μL receiving direct-acting antiviral (DAA) therapy with at least 12-weeks post-treatment follow-up (PTW12) were enrolled. Significant platelet count improvement was defined as a ≥10% increase in platelet counts at PTW12 from baseline. Platelet count evolution at treatment week 4, end-of-treatment, PTW12, and PTW48 was evaluated. This study included 4922 patients. Sustained virologic response after 12 weeks post-treatment was achieved in 98.7% of patients. Platelet counts from baseline, treatment week 4, and end-of-treatment to PTW12 were 108.8 ± 30.2, 121.9 ± 41.1, 123.1 ± 43.0, and 121.1 ± 40.8 × 103/μL, respectively. Overall, 2230 patients (45.3%) showed significant platelet count improvement. Multivariable analysis revealed that age (odds ratio (OR) = 0.99, 95% confidence interval (CI): 0.99–1.00, p = 0.01), diabetes mellitus (DM) (OR = 1.20, 95% CI: 1.06–1.38, p = 0.007), cirrhosis (OR = 0.66, 95% CI: 0.58–0.75, p < 0.0001), baseline platelet counts (OR = 0.99, 95% CI: 0.98–0.99, p < 0.0001), and baseline total bilirubin level (OR = 0.80, 95% CI: 0.71–0.91, p = 0.0003) were independent predictive factors of significant platelet count improvement. Subgroup analyses showed that patients with significant platelet count improvement and sustained virologic responses, regardless of advanced fibrosis, had a significant increase in platelet counts from baseline to treatment week 4, end-of-treatment, PTW12, and PTW48. Young age, presence of DM, absence of cirrhosis, reduced baseline platelet counts, and reduced baseline total bilirubin levels were associated with significant platelet count improvement after DAA therapy in thrombocytopenic CHC patients.Keywords
Funding Information
- Kaohsiung Medical University (KMU-KI110002)
- Kaohsiung Medical University Research Center Grant, Center for Liquid Biopsy and Cohort Research (KMU-TC109B05)
- Kaohsiung Medical University Research Center Grant, Center for Cancer Research (KMU-TC109A04, KMU-TC108B07 and KMU-DK109002)
- Kaohsiung Medical University Chung-Ho Memorial Hospital (KMUH109-9R06, KMUH-DK(C)110011)
This publication has 34 references indexed in Scilit:
- Quantification of Core Antigen Monitors Efficacy of Direct-acting Antiviral Agents in Patients With Chronic Hepatitis C Virus InfectionClinical Gastroenterology and Hepatology, 2016
- Improvement of platelets after SVR among patients with chronic HCV infection and advanced hepatic fibrosisJournal of Gastroenterology and Hepatology, 2015
- Mechanisms of Chronic State of Inflammation as Mediators That Link Obese Adipose Tissue and Metabolic SyndromeMediators of Inflammation, 2013
- Improvement of Thrombocytopenia in Hepatitis C-Related Advanced Fibrosis Patients After Sustained Virological ResponseDigestive Diseases and Sciences, 2012
- Treating hepatitis C: current standard of care and emerging direct‐acting antiviral agentsJournal of Viral Hepatitis, 2012
- Longitudinal changes of the laboratory data of chronic hepatitis C patients with sustained virological response on long‐term follow‐upJournal of Viral Hepatitis, 2011
- Prevalence of thrombocytopenia among patients with chronic hepatitis C: a systematic reviewJournal of Viral Hepatitis, 2010
- Hepatitis C virus viremia and low platelet count: A study in a hepatitis B & C endemic area in TaiwanJournal of Hepatology, 2010
- Platelet and White Blood Cell Counts Are Elevated in Patients With the Metabolic SyndromeThe Journal of Clinical Hypertension, 2005
- Nonalcoholic Fatty Liver, Steatohepatitis, and the Metabolic SyndromeHepatology, 2003